Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results

Investor Takeaways

Revenue of ₹2,809 Cr in Q3FY25 showed sequential growth from ₹2,859 Cr in Q1FY25, indicating stable top-line performance.

Net profit of ₹503 Cr in Q3FY25 reflected improved profitability compared to ₹457 Cr in Q1FY25, with OPM expanding to 32.54% from 31.62%.

Final dividend of [amount context mismatch] per share and interim dividend of ₹29.00 per share declared, totaling [amount not verified]per share for the fiscal year.

Market Cap of ₹1,49,108.91 Cr and P/E Ratio of 80.06 indicate premium valuation relative to peers.

Overall Tone: Neutral

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹2,809 Cr (Q3FY25)	N/A
Net Profit	₹503 Cr (Q3FY25)	N/A
EBITDA	Not available	N/A
EPS	[amount context mismatch] (Q3FY25)	N/A
OPM	32.54% (Q3FY25)	N/A

What Changed

Torrent Pharmaceuticals concluded its 53rd Annual General Meeting on 23 June 2026, where shareholders approved the standalone and consolidated financial statements for the fiscal year ended 31 March 2026. The company declared an interim dividend of ₹29.00 per share and a final dividend of ₹9.00 per share, reflecting a consistent dividend payout policy. Additionally, a new director was appointed to the board, replacing Samir Mehta. The approved financials were supported by quarterly performance showing revenue of ₹2,809 Cr in Q3FY25, up from ₹2,745 Cr in Q4FY24, with net profit rising to ₹503 Cr from ₹449 Cr. Operating profit margin improved to 32.54% from 32.17% in the prior quarter. The company’s market capitalization stood at ₹1,49,108.91 Cr, with a P/E ratio of 80.06, indicating market expectations of sustained growth. Peer comparisons reveal that Torrent’s P/E ratio is significantly higher than Sun Pharmaceutical (41.28), Divi's Laboratories (72.41), and Apollo Hospitals (64.49), suggesting a premium valuation. However, its ROE and ROCE figures were not provided in the filing, limiting direct profitability assessment against peers.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Torrent Pharmaceuticals	80.06	Not available	Not available	1,49,108.91
Sun Pharmaceutical	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories	72.41	16.56%	22.09%	1,79,470.03
Apollo Hospitals	64.49	21.94%	20.5%	1,16,213.95

Torrent Pharmaceuticals trades at a higher P/E multiple compared to its peers, suggesting market optimism about future earnings growth. However, its ROE and ROCE metrics were not disclosed in the provided data, preventing a full assessment of capital efficiency relative to peers like Divi's Laboratories and Apollo Hospitals, which report ROE above 15% and ROCE above 20%.

Risks & Concerns

No specific risks were identified in the filing. The company emphasized shareholder-friendly policies and stable financial performance.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	2,809	503	32.54
Q2FY25	2,889	453	32.50
Q1FY25	2,859	457	31.62
Q4FY24	2,745	449	32.17

📄 View Original Announcement (PDF)

📊 Stock Analysis — TORNTPHARM ✨ Ask AI About This

About Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,49,108.91 Cr P/E: 80.1

View full TORNTPHARM stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when TORNTPHARM files new disclosures

Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TORNTPHARM — Free

Free account · 2 AI queries/day